Efficacy of 5-Aminolaevulinic acid photodynamic therapy combined with human interferon α-2β in the treatment of condyloma acuminatum
- VernacularTitle:5-氨基酮戊酸光动力疗法联合人干扰素α-2β治疗尖锐湿疣的效果分析
- Author:
Yuhui FANG
1
;
Xinyi WANG
;
Kunpeng LI
;
Wei WANG
Author Information
- Publication Type:Research Article
- Keywords: 5-Aminolevulinic acid photodynamic therapy; human interferon α-2β; condyloma acuminatum; chemokine ligand 19; matrix metalloproteinase-3
- From: Journal of Clinical Medicine in Practice 2024;28(20):27-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects of 5-Aminolaevulinic acid photodynamic therapy (ALA-PDT) combined with human interferon α-2β in the treatment of condyloma acuminatum (CA) and its impacts on serum T-cell subsets, chemokine ligand 19 (CCL19), and matrix metalloproteinase-3 (MMP-3) levels. Methods A total of 86 patients with CA were enrolled and randomly divided to control group (treated with ALA-PDT alone) and observation group (treated with ALA-PDT combined with human interferon α-2β), with 43 patients in each group. Clinical efficacy, changes in serum T-cell subsets, CCL19, and MMP-3 levels before and after treatment were compared between the two groups. Adverse reactions during treatment were recorded. Patients were followed up for 6 months to record the number of warts and recurrence rate. Results The total effective rate of treatment in the observation group was significantly higher than that in the control group (
P < 0.05). After treatment, the levels of CD4+, CD8+, and CD4+/CD8+ in the observation group were significantly elevated compared to the control group (P < 0.05). Additionally, serum CCL19 levels increased, while MMP-3 levels decreased in the observation group post-treatment compared to the control group (P < 0.05). No significant difference was observed in the incidence of adverse reactions between the two groups (P >0.05). The recurrence rate and the number of average recurrent warts were significantly higher in the control group than in the observation group (P < 0.05). Conclusion The combination of ALA-PDT and human interferon α-2β exhibits remarkable efficacy in the treatment of CA, which can effectively regulate serum T-cell subset levels, reduce MMP-3 levels, enhance CCL19 levels, and demonstrates good safety.
